Global Patent Index - EP 2912179 A4

EP 2912179 A4 20161012 - C-MYC ANTISENSE OLIGONUCLEOTIDES AND METHODS FOR USING THE SAME TO TREAT CELL-PROLIFERATIVE DISORDERS

Title (en)

C-MYC ANTISENSE OLIGONUCLEOTIDES AND METHODS FOR USING THE SAME TO TREAT CELL-PROLIFERATIVE DISORDERS

Title (de)

C-MYC-ANTISENSE-OLIGONUKLEOTIDE UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG VON AUF DAS ZELLWACHSTUM WIRKENDEN ERKRANKUNGEN

Title (fr)

OLIGONUCLÉOTIDES ANTISENS C-MYC ET SES PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DE TROUBLES DE LA PROLIFÉRATION CELLULAIRE

Publication

EP 2912179 A4 20161012 (EN)

Application

EP 13849097 A 20131025

Priority

  • US 201261719348 P 20121026
  • US 201313829594 A 20130314
  • US 201361784910 P 20130314
  • US 2013066960 W 20131025

Abstract (en)

[origin: WO2014066851A1] Provided herein are antisense oligonucleotides that can effectively prevent or decrease c-myc protein expression as well as decrease overall rates of cell proliferation in in vitro and mammalian in vivo models of cell proliferative disorders as well as methods for using the same. The antisense oligonucleotides comprise at least one phosphoramidate (NP)-modified or thiophosphoramidate (NPS)-modified intersubunit linkage.

IPC 8 full level

C12N 15/113 (2010.01); A61K 31/7125 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP)

A61K 31/7125 (2013.01); A61P 35/00 (2018.01); C12N 15/1135 (2013.01); C12N 2310/111 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); C12N 2310/345 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/3517 (2013.01)

Citation (search report)

  • [Y] WO 9736005 A1 19971002 - LYNX THERAPEUTICS INC [US], et al
  • [Y] US 6867294 B1 20050315 - SANGHVI YOGESH S [US], et al
  • [A] WO 0118015 A1 20010315 - GERON CORP [US], et al
  • [A] WO 2005023994 A2 20050317 - GERON CORP [US], et al
  • [A] WO 2011075656 A1 20110623 - UNIV BRITISH COLUMBIA [CA], et al
  • [A] WO 0183740 A2 20011108 - AVI BIOPHARMA INC [US]
  • [A] T. SKORSKI ET AL: "Antileukemia effect of c-myc N3'->P5' phosphoramidate antisense oligonucleotides in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 8, 15 April 1997 (1997-04-15), US, pages 3966 - 3971, XP055271471, ISSN: 0027-8424, DOI: 10.1073/pnas.94.8.3966
  • [A] GRYAZNOV, S.: "Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 131 - 140, XP055271472, ISSN: 0006-3002
  • [A] GRYAZNOV S ET AL: "OLIGONUCLEOTIDE N3'-P5' PHOSPHORAMIDATES AS ANTISENSE AGENTS", NUCLEIC ACIDS RESEARCH, vol. 24, no. 8, 15 April 1996 (1996-04-15), pages 1508 - 1514, XP000582450, ISSN: 0305-1048, DOI: 10.1093/NAR/24.8.1508
  • See also references of WO 2014066851A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014066851 A1 20140501; CA 2887702 A1 20140501; CA 2887702 C 20230801; CA 3201145 A1 20140501; EP 2912179 A1 20150902; EP 2912179 A4 20161012; HK 1214293 A1 20160722

DOCDB simple family (application)

US 2013066960 W 20131025; CA 2887702 A 20131025; CA 3201145 A 20131025; EP 13849097 A 20131025; HK 16102007 A 20160223